Moderna, Inc. Cash and Restricted Cash
Moderna, Inc. (MRNA) had Cash and Restricted Cash of $1.72 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-31
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.72B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.91B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.60B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.13B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $1.72B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $1.91B 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $2.60B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $1.13B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.28B 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $1.63B 10-Q · filed 2026-05-01 | |
| 2024-12-31 | $1.93B 10-Q · filed 2026-07-31 | |
| 2024-09-30 | $1.65B 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.48B 10-Q · filed 2025-08-01 | |
| 2024-03-31 | $2.07B 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $2.93B 10-K · filed 2026-02-20 | |
| 2023-09-30 | $2.95B 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $3.82B 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $3.46B 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $3.22B 10-K · filed 2026-02-20 | |
| 2022-09-30 | $3.04B 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $2.88B 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $5.06B 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $6.86B 10-K · filed 2025-02-21 | |
| 2021-09-30 | $5.56B 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $5.61B 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $5.45B 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $2.64B 10-K · filed 2024-02-23 | $2.64B 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.52B 10-Q · filed 2021-11-04 | $1.52B 10-Q · filed 2020-10-30 |
| 2020-06-30 | $1.77B 10-Q · filed 2021-08-05 | $1.77B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $404.00M 10-Q · filed 2021-05-06 | $403.54M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $248.00M 10-K · filed 2023-02-24 | $247.70M 10-K · filed 2020-02-27 |
| 2019-09-30 | $185.53M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $163.45M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $514.76M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $670.00M 10-K · filed 2022-02-25 | $670.49M 10-Q · filed 2019-05-09 |
| 2018-09-30 | $179.42M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $152.98M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $102.51M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $147.61M 10-K · filed 2021-02-26 | |
| 2016-12-31 | $61.56M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |